Suppr超能文献

同步免疫改变反映了变应原免疫治疗过程中的临床反应。

Synchronous immune alterations mirror clinical response during allergen immunotherapy.

机构信息

Benaroya Research Institute at Virginia Mason, Seattle, Wash.

Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Section of Inflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London, United Kingdom; MRC and Asthma UK, Centre in Allergic Mechanisms of Asthma, London, United Kingdom.

出版信息

J Allergy Clin Immunol. 2018 May;141(5):1750-1760.e1. doi: 10.1016/j.jaci.2017.09.041. Epub 2017 Nov 9.

Abstract

BACKGROUND

Three years of treatment with either sublingual or subcutaneous allergen immunotherapy has been shown to be effective and to induce long-term tolerance. The Gauging Response in Allergic Rhinitis to Sublingual and Subcutaneous Immunotherapy (GRASS) trial demonstrated that 2 years of treatment through either route was effective in suppressing the response to nasal allergen challenge, although it was insufficient for inhibition 1 year after discontinuation.

OBJECTIVE

We sought to examine in the GRASS trial the time course of immunologic changes during 2 years of sublingual and subcutaneous immunotherapy and for 1 year after treatment discontinuation.

METHODS

We performed multimodal immunomonitoring to assess allergen-specific CD4 T-cell properties in parallel with analysis of local mucosal cytokine responses induced by nasal allergen exposure and humoral immune responses that included IgE-dependent basophil activation and measurement of serum inhibitory activity for allergen-IgE binding to B cells (IgE-facilitated allergen binding).

RESULTS

All 3 of these distinct arms of the immune response displayed significant and coordinate alterations during 2 years of allergen desensitization, followed by reversal at 3 years, reflecting a lack of a durable immunologic effect. Although frequencies of antigen-specific T2 cells in peripheral blood determined by using HLA class II tetramer analysis most closely paralleled clinical outcomes, IgE antibody-dependent functional assays remained inhibited in part 1 year after discontinuation.

CONCLUSION

Two years of allergen immunotherapy were effective but insufficient for long-term tolerance. Allergen-specific T2 cells most closely paralleled the transient clinical outcome, and it is likely that recurrence of the T-cell drivers of allergic immunity abrogated the potential for durable tolerance. On the other hand, the persistence of IgE blocking antibody 1 year after discontinuation might be an early indicator of a protolerogenic mechanism.

摘要

背景

舌下或皮下过敏原免疫治疗 3 年已被证明有效,并可诱导长期耐受。变应性鼻炎舌下和皮下免疫治疗反应评估(GRASS)试验表明,两种途径治疗 2 年均能有效抑制鼻过敏原激发的反应,但在停药 1 年后抑制作用不足。

目的

我们在 GRASS 试验中寻求检查舌下和皮下免疫治疗 2 年期间以及治疗停止后 1 年内免疫变化的时间过程。

方法

我们进行了多模式免疫监测,以平行评估过敏原特异性 CD4 T 细胞特性,同时分析鼻过敏原暴露诱导的局部黏膜细胞因子反应以及体液免疫反应,包括 IgE 依赖性嗜碱性粒细胞激活和测量血清抑制活性,用于过敏原-IgE 与 B 细胞结合(IgE 促进过敏原结合)。

结果

在 2 年的过敏原脱敏过程中,这 3 种不同的免疫反应均显示出显著而协调的改变,随后在 3 年时逆转,反映出缺乏持久的免疫效应。虽然使用 HLA Ⅱ类四聚体分析确定的外周血中抗原特异性 T2 细胞的频率最接近临床结果,但 IgE 抗体依赖性功能测定在停药后 1 年仍部分受到抑制。

结论

2 年的过敏原免疫治疗是有效的,但不足以实现长期耐受。过敏原特异性 T2 细胞最接近短暂的临床结果,很可能是过敏免疫的 T 细胞驱动因素的复发破坏了持久耐受的潜力。另一方面,停药后 1 年持续存在 IgE 阻断抗体可能是一种耐受原性机制的早期指标。

相似文献

1
Synchronous immune alterations mirror clinical response during allergen immunotherapy.
J Allergy Clin Immunol. 2018 May;141(5):1750-1760.e1. doi: 10.1016/j.jaci.2017.09.041. Epub 2017 Nov 9.
2
Intradermal grass pollen immunotherapy increases T2 and IgE responses and worsens respiratory allergic symptoms.
J Allergy Clin Immunol. 2017 Jun;139(6):1830-1839.e13. doi: 10.1016/j.jaci.2016.09.024. Epub 2016 Oct 20.
4
Nasal allergen-neutralizing IgG antibodies block IgE-mediated responses: Novel biomarker of subcutaneous grass pollen immunotherapy.
J Allergy Clin Immunol. 2019 Mar;143(3):1067-1076. doi: 10.1016/j.jaci.2018.09.039. Epub 2018 Nov 14.
5
Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
J Allergy Clin Immunol. 2012 Nov;130(5):1108-1116.e6. doi: 10.1016/j.jaci.2012.07.056. Epub 2012 Sep 27.
6
Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation.
J Allergy Clin Immunol. 2014 Jan;133(1):130-8.e1-2. doi: 10.1016/j.jaci.2013.09.043. Epub 2013 Nov 28.
8
Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.
J Allergy Clin Immunol. 2011 Feb;127(2):509-516.e1-5. doi: 10.1016/j.jaci.2010.12.1080.
10
Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.
Allergy. 2012 Feb;67(2):217-26. doi: 10.1111/j.1398-9995.2011.02745.x. Epub 2011 Nov 14.

引用本文的文献

2
Biomarker-driven drug development for allergic diseases and asthma: An FDA public workshop.
J Allergy Clin Immunol. 2025 Jun;155(6):1753-1766. doi: 10.1016/j.jaci.2025.03.014. Epub 2025 Mar 26.
4
Treatment of Allergic Rhinitis with Acupuncture Based on Pathophysiological.
Int J Gen Med. 2024 Jun 12;17:2741-2756. doi: 10.2147/IJGM.S470949. eCollection 2024.
5
Biomarkers in allergen immunotherapy: Focus on eosinophilic inflammation.
Asia Pac Allergy. 2024 Mar;14(1):32-38. doi: 10.5415/apallergy.0000000000000129. Epub 2023 Dec 18.
6
Efficacy and immunological changes of sublingual immunotherapy in pediatric allergic rhinitis.
World Allergy Organ J. 2023 Jul 23;16(7):100803. doi: 10.1016/j.waojou.2023.100803. eCollection 2023 Jul.
7
Distinct CRTH2+CD161+ (peTh2) memory CD4+ T-cell cytokine profiles in food allergy and eosinophilic gastrointestinal disorders.
Clin Exp Allergy. 2023 Oct;53(10):1031-1040. doi: 10.1111/cea.14376. Epub 2023 Jul 24.
8
Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy.
J Allergy Clin Immunol. 2023 Nov;152(5):1247-1260. doi: 10.1016/j.jaci.2023.06.025. Epub 2023 Jul 15.
9
Silencing SOX11 Alleviates Allergic Rhinitis by Inhibiting Epithelial-Derived Cytokines.
Balkan Med J. 2023 Jan 23;40(1):57-65. doi: 10.4274/balkanmedj.galenos.2022.2022-9-31. Epub 2022 Dec 26.
10
Immunology of allergen immunotherapy.
Immunother Adv. 2022 Nov 25;2(1):ltac022. doi: 10.1093/immadv/ltac022. eCollection 2022.

本文引用的文献

3
Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults.
J Allergy Clin Immunol. 2017 Apr;139(4):1242-1252.e9. doi: 10.1016/j.jaci.2016.08.017. Epub 2016 Oct 26.
4
Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.
J Allergy Clin Immunol. 2017 Jan;139(1):173-181.e8. doi: 10.1016/j.jaci.2016.05.027. Epub 2016 Aug 10.
5
Potential Mechanisms for IgG4 Inhibition of Immediate Hypersensitivity Reactions.
Curr Allergy Asthma Rep. 2016 Mar;16(3):23. doi: 10.1007/s11882-016-0600-2.
6
SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis.
Allergy Asthma Proc. 2016 Mar-Apr;37(2):92-104. doi: 10.2500/aap.2016.37.3937. Epub 2016 Jan 21.
7
Oral Immunotherapy for Food Allergy.
Immunol Allergy Clin North Am. 2016 Feb;36(1):55-69. doi: 10.1016/j.iac.2015.08.007.
9
Chronic cat allergen exposure induces a TH2 cell-dependent IgG4 response related to low sensitization.
J Allergy Clin Immunol. 2015 Dec;136(6):1627-1635.e13. doi: 10.1016/j.jaci.2015.07.031. Epub 2015 Sep 11.
10
The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease.
Allergy. 2015 Nov;70(11):1393-405. doi: 10.1111/all.12698. Epub 2015 Sep 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验